Situs Corp. Announces Appointment of Malcolm Heaven as Chief Technology Officer and Vice President of Research and Development and Operations

Solana Beach, California, UNITED STATES


SOLANA BEACH, Calif., Oct. 25, 1999 (PRIMEZONE) - Situs Corp., a leader in the development of alternate drug delivery systems, today announced the appointment of Malcolm Heaven as Chief Technology Officer and Vice President of Research and Development and Operations.

Prior to joining Situs, Mr. Heaven was Senior Vice President of Corporate Research and Development for Imagyn Medical Technologies, Inc., where he was responsible for all development activities supporting the Urology, Surgical, Gynecology, Critical Care/Anesthesiology and Medical/Surgical Divisions of the company. At Imagyn, Mr. Heaven was also responsible for managing all patent activity and was involved in technical due diligence for all acquisitions and technology licenses.

Earlier, Mr. Heaven was Vice President and Chief Technology Officer of Advanced Surgical, Inc. and has spent more than 30 years in the biotechnology and materials science industries. He is a graduate of the College of Advanced Technology in Birmingham, England.

W. Tate Scott, President and Chief Executive Officer of Situs, said "We are very pleased to have Malcolm Heaven join the Situs team, particularly during this critical period in which we have begun testing our products. We are looking forward to the wisdom and contribution he will make to the company as we move forward with all of our exciting new products."

Situs recently announced it is initiating Phase I/II human clinical testing of its proprietary drug (I-OXY() for treatment of overactive bladder and will file shortly to secure FDA approval to begin clinical testing for its intravesical drug delivery system (UROS) designed to continuously deliver drugs to the bladder.

Situs Corporation is a developer of alternate drug delivery systems. The company's site-specific drug delivery platform is capable of administering various pharmaceutical compounds for the treatment of local and systemic conditions.

The company's first target indication, overactive bladder, affects an estimated 17 million Americans, more than 30 percent of whom cannot tolerate the side effects of oral medications. Other potential applications of the Situs system include chemotherapeutic agents for bladder cancer, hormones for genitourinary conditions, and analgesics for pain.

                    

        

Contact Data